Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C

Clinical Trial Summary

This study will collect and evaluate information on the safety and efficacy of Sovaldi-based regimens in routine clinical practice in Mexico. The primary objective of this study is to assess the rates of serious adverse events/reactions (SAEs/SADRs) and adverse events/reactions (AEs/ADRs) in adult participants with chronic hepatitis C virus (HCV) infection treated with Sovaldi in routine clinical practice.

See also
Status	Clinical Trial	Phase
Completed	`NCT03674125` - Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection	Phase 1
Completed	`NCT00978497` - Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection	Phase 2
Completed	`NCT00170131` - MMF Influence on HCV Viral Evolution After Liver Transplantation	Phase 4
Completed	`NCT04008927` - A Community-based Intervention Among Active Drug Users in Montpellier	N/A
Active, not recruiting	`NCT04044586` - HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
Completed	`NCT01958281` - Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency	Phase 2
Completed	`NCT02533427` - Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol	Phase 1
Withdrawn	`NCT04309734` - Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects	Phase 1/Phase 2
Completed	`NCT01965535` - Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection	Phase 2
Completed	`NCT00743795` - Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection	Phase 2
Completed	`NCT00768690` - A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333	Phase 1
Withdrawn	`NCT04235049` - Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)	Phase 4
Terminated	`NCT00401947` - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection	Phase 2
Completed	`NCT00959699` - A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)	Phase 2
Completed	`NCT00623649` - Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection	Phase 1
Completed	`NCT00221624` - Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients	Phase 3
Completed	`NCT04134767` - Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)	N/A
Completed	`NCT02402452` - Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment	Phase 1
Completed	`NCT00909636` - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet	Phase 1
Completed	`NCT00909311` - Study in Healthy Adults to Evaluate Effect of Food on Pharmacokinetics, Safety and Tolerability of ABT-450 With Ritonavir	Phase 1

NCT number	NCT02783976
Study type	Observational
Source	Gilead Sciences
Contact
Status	Completed
Phase
Start date	October 28, 2016
Completion date	June 20, 2018

Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms